A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects With Late-onset Pompe Disease

Status: Terminated
Location: See all (22) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

Study 701-301 is a single-arm, open-label, switchover study in patients with late-onset Pompe disease who have been receiving treatment with recombinant human acid alpha-glucosidase (rhGAA) for 48 weeks or longer. Ambulatory patients who have mild to moderate respiratory impairment will switch directly to receive BMN 701 20 mg/kg by IV infusion every other week. All participants will receive active drug. No dose of existing therapy will be missed - experimental drug is started immediately.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: No
View:

• Willing and able to provide written informed consent, after the nature of the study has been explained, and prior to any study-related procedures.

• Diagnosed with late-onset Pompe disease based on 2 currently or previously documented GAA gene mutations, and endogenous GAA activity <75% of the lower limit of the normal adult range reported by the testing laboratory, as assessed by dried blood spot or whole blood assay.

• Has received prior treatment with commercial rhGAA as defined by ALL of the following:

• has received treatment with commercial rhGAA for ≥ 48 weeks (but no more than 20% of the study population can have received treatment for ≥ 6 years).

• has received > 80% of all scheduled treatments in the prior 48 weeks and ≥ 4 out of the prior 6 scheduled treatments.

• has received and completed the last two infusions without a drug-related adverse event resulting in dose interruption.

• has received last treatment of commercial rhGAA ≥ 10 and ≤ 31 days prior to anticipated initiation of treatment with BMN 701.

• ≥ 18 years of age at the time of enrollment in the study.

• Sexually active subjects must be willing to use two known effective methods of contraception while participating in the study and for at least 4 months following the last dose of BMN 701.

• Females of childbearing potential must have a negative pregnancy test at Screening and Baseline visits and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to Screening, or who have had total hysterectomy.

• Has ≥ 30% predicted upright FVC and < 80% predicted upright FVC.

• Has ≤60% predicted MIP.

• Is able to ambulate ≥75 meters and ≤500 meters on the 6MWT conducted during the Screening visit (use of assistive devices such as walker, cane, or crutches, is permitted with consistent use throughout the study).

• Is willing and able to comply with all study procedures.

Locations
United States
Arizona
Neuromuscular Research Centre
Phoenix
California
University of California, Irvine
Orange
Florida
University of Florida
Gainesville
Kansas
University of Kansas Medical Center
Kansas City
Missouri
Washington University
Saint Louis
North Carolina
Duke University Medical Center
Durham
Ohio
The Ohio State University - Wexner Medical Center
Columbus
Utah
University of Utah
Salt Lake City
Other Locations
Belgium
Antwerp University Hospital (UZA)
Edegem
France
Hôpital Raymond Poincaré
Garches
CHU de la Timone
Marseille
Germany
Villa Metabolica, ZKJM MC University Mainz
Mainz
Klinikum der Universität München
München
Universitätsklinikum Münster
Münster
Italy
Azienda Ospedaliera Universitaria Policlinico G. Martino - Messina
Messina
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Milano
Netherlands
Erasmus MC University Medical Center
Rotterdam
Portugal
Centro Hospitalar de Sao Joao, EPE
Porto
United Kingdom
University Hospital Birmingham
Birmingham
National Hospital for Neurology and Neurosurgery
London
Royal Free Hospital
London
Salford Royal NHS Foundation Trust
Salford
Time Frame
Start Date: April 2014
Completion Date: September 12, 2016
Participants
Target number of participants: 24
Treatments
Experimental: BMN 701 20 mg/kg
BMN 701 IV Infusion 20mg/kg every 2 weeks for 24 weeks followed by an optional extension of 240 weeks (total duration of therapy 264 weeks)
Related Therapeutic Areas
Sponsors
Leads: BioMarin Pharmaceutical

This content was sourced from clinicaltrials.gov

Similar Clinical Trials